See the DrugPatentWatch profile for Guselkumab
What is Guselkumab and Why is it a Target for Biosimilars?
Guselkumab is a medication used to treat moderate-to-severe psoriasis, a chronic skin condition characterized by inflamed, scaly patches on the skin. It belongs to a class of drugs called interleukin-23 (IL-23) inhibitors, which work by blocking the action of IL-23, a molecule that plays a key role in the development of psoriasis [1].
Developed by Janssen Pharmaceuticals, guselkumab has been shown to be effective in Phase III clinical trials in improving skin symptoms and achieving significant clinical responses in patients with moderate-to-severe psoriasis [2].
Why are Companies Challenging the Patent?
The patent for guselkumab expired in [Patent expiration year] [3]. However, companies are still developing biosimilars, as it may take time to complete the development and regulatory approval process for these medicines.
The potential market for biosimilars of guselkumab is significant, given the high cost and demand for this medication. According to DrugPatentWatch.com, the global psoriasis market is projected to reach $13.6 billion by 2027 [4].
How do Biosimilars Enter the Market?
Biosimilars can enter the market once the original patent expires. However, the development of biosimilars is a complex process that involves conducting clinical trials to demonstrate their safety and efficacy.
To gain approval, biosimilars must be highly similar to the reference product in terms of quality, safety, and efficacy. The biosimilar developer must also demonstrate that their product meets the same standards as the reference product.
Who Makes Biosimilars of Guselkumab?
Several companies are in the process of developing biosimilars of guselkumab, including [list companies]. These companies are working to gain regulatory approval and bring their products to market.
When Can Biosimilars Be Expected to Enter the Market?
The exact timeline for the entry of biosimilars into the market is difficult to predict. However, it may take several years after the patent expiration date for these products to become available.
What is the Regulatory Path for Biosimilars?
The regulatory path for biosimilars is governed by various laws and regulations, including the Biologics Price Competition and Innovation Act (BPCIA) in the United States. This law provides a framework for the development, approval, and marketing of biosimilars.
Sources:
[1] Janssen Pharmaceuticals. (2020). TREATTMENT INFORMATION FOR GUSELKUMAB.
[2] Reich K, et al. (2017). Guselkumab, an anti-interleukin-23 monoclonal antibody, in psoriasis. The Lancet, 390(10088), 2310-2318.
[3] DrugPatentWatch.com. (n.d.). Guselkumab - Patents Overview.
[4] DrugPatentWatch.com. (n.d.). Psoriasis - Market Overview.